

Serine/Threonine Protein Kinase ATR - Pipeline Review, H1 2020

<https://marketpublishers.com/r/S191145DD6E2EN.html>

Date: February 2020

Pages: 65

Price: US\$ 3,500.00 (Single User License)

ID: S191145DD6E2EN

Abstracts

Serine/Threonine Protein Kinase ATR - Pipeline Review, H1 2020

SUMMARY

Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The latest report SerineThreonine Protein Kinase ATR - Pipeline Review, H1 2020, outlays comprehensive information on the Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Serine/threonine-protein kinase ATR is an enzyme encoded by the ATR gene. It is required for cell cycle arrest and DNA damage repair in response to DNA damage. It has shown to phosphorylate checkpoint kinase CHK1, checkpoint proteins RAD17, and RAD9, as well as tumor suppressor protein BRCA1. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 8 and 3 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively.

Report covers products from therapy areas Oncology which include indications Ovarian Cancer, Solid Tumor, Fallopian Tube Cancer, Peritoneal Cancer, Triple-Negative Breast Cancer (TNBC), Cervical Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer,

Pancreatic Cancer, Small-Cell Lung Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Breast Cancer, Endometrial Cancer, Epithelial Ovarian Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Renal Cell Carcinoma, Non-Hodgkin Lymphoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Bile Duct Cancer (Cholangiocarcinoma), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Chronic Myelomonocytic Leukemia (CMML), Esophageal Cancer, Gastric Cancer, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Kidney Cancer (Renal Cell Cancer), Leiomyosarcoma, Lung Cancer, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Pancreatic Cancer, Myelodysplastic Syndrome, Neuroendocrine Cancer, Osteosarcoma, Pancreatic Ductal Adenocarcinoma, Peritoneal Tumor, Prostate Cancer, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Transitional Cell Cancer (Urothelial Cell Cancer) and Uterine Cancer.

Furthermore, this report also reviews key players involved in Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1)

The report reviews Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Overview

Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Companies Involved in

Therapeutics Development

Artios Pharma Ltd

AstraZeneca Plc

Atrin Pharmaceuticals LLC

Bayer AG

Biokine Therapeutics Ltd

Cybrexa Inc

IMPACT Therapeutics Inc

Merck KGaA

Pfizer Inc

Repare Therapeutics Inc

Vertex Pharmaceuticals Inc

Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Drug Profiles

ATRN-119 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATRN-212 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
AZ-20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1895344 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
berzosertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BKT-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBX-13 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ceralasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ceralasertib + olaparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMP-09 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-1774 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

M-4344 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-3500 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit ATR for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit ATR for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ATR for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VE-821 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Dormant Products

Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Discontinued Products

Serine/Threonine Protein Kinase ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Product Development Milestones

Featured News & Press Releases

Sep 23, 2019: Merck KGaA to announce data of M6620 at ESMO 2019 Congress

May 13, 2019: Bayer to present abstract on on investigational ATR inhibitor BAY 1895344 at ASCO 2019

Oct 09, 2018: Merck KGaA to announce data of M6620 at ESMO 2018 Congress

May 16, 2018: Merck's M6620 Data at ASCO 2018 to Showcase Progress and Further Optionality of Oncology Pipeline

Aug 30, 2017: Merck To Present Data On M6620 At ESMO 2017

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Artios Pharma Ltd, H1 2020
Pipeline by AstraZeneca Plc, H1 2020
Pipeline by Atrin Pharmaceuticals LLC, H1 2020
Pipeline by Bayer AG, H1 2020
Pipeline by Biokine Therapeutics Ltd, H1 2020
Pipeline by Cybrexa Inc, H1 2020
Pipeline by IMPACT Therapeutics Inc, H1 2020
Pipeline by Merck KGaA, H1 2020
Pipeline by Pfizer Inc, H1 2020
Pipeline by Repare Therapeutics Inc, H1 2020
Pipeline by Vertex Pharmaceuticals Inc, H1 2020
Dormant Projects, H1 2020
Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

COMPANIES MENTIONED

Artios Pharma Ltd

AstraZeneca Plc

Atrin Pharmaceuticals LLC

Bayer AG

Biokine Therapeutics Ltd

Cybrexa Inc

IMPACT Therapeutics Inc

Merck KGaA

Pfizer Inc

Repare Therapeutics Inc

Vertex Pharmaceuticals Inc

I would like to order

Product name: Serine/Threonine Protein Kinase ATR - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/S191145DD6E2EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S191145DD6E2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970